Saya Jacob

@AlexisLevee @laura_huppert @UCSFCancer Thank you!!

@laura_huppert @UCSFCancer @SayaJacob3 Congratulations!! Very well-done 👏 @SayaJacob3

Beautiful presentation by ⭐️ @UCSFCancer fellow @SayaJacob3 about incidence of delayed IRAEs. Retrospective analysis of 300+ pt- 25% rate delayed toxicity (>90d post-ICI start) & 7.5% post-tx, mostly endocrine. Prior early IRAE= ⬆️ late IRAEs. Need to keep monitoring post ICI!

Incredible discussion of the INAVO120 by @hoperugo. Significant PFS benefit with encouraging OS results. Need to think critically about the population (only 2 Black/AA patients, large proportion of patients receiving adjuvant tam alone, low Hgb A1C cut off) @SABCSSanAntonio

@royaryam @laura_huppert @UCSFCancer Thank you!!!

@laura_huppert @UCSFCancer @SayaJacob3 Congratulations @SayaJacob3

Incredible summary of the latest updates in immunotherapy for HR+ and TNBC by @laura_huppert Can the pCR benefit seen with the addition of checkpoint inhibitors with chemotherapy in HR+ disease translate to EFS? In TNBC, do we need neoadjuvant and adjuvant ICI?

@DrSGraff @OncLive @hoperugo @UCSFCancer Thank you so much!

Presenting her data on delayed / post-tx immune AE as part of #SABCS23 @OncLive National Fellows Forum - Dr @SayaJacob3

Important analysis from #KATHERINE now published on Breast NPJ. Do patients with HER2 switch (pos->neg) after NACT still benefit from adjuvant T-DM1? This happened in 8.3% (70/845) of KATHERINE patients, & those in the T-DM1 arm clearly had improved iDFS. nature.com/articles/s4152…